ASTON, Pa. -- Innocoll, Inc. announced that its wholly owned subsidiary, Syntacoll AG, has been granted two important patents. U.S. Patent No. 6,855,860 entitled Composite Dressings for Treatment of Wounds was issued by the United States Patent and Trademark Office and patent No. 1263485 entitled Multilayer Collagen Matrix for Tissue Reconstruction by the European Patent Office.
The U.S. patent covers a product comprised of a novel collagen-based composite material designed for the treatment of deep wounds, or wounds that penetrate the middle and deepest layers of skin, or dermis. These deep wounds occur in second- or third-degree burns and in a variety of acute and/or chronic skin disorders, such as leg ulcers and pressure ulcers.
The EU patent covers the use and manufacture of multi-layer collagen-based matrices for surgical applications including tissue and organ reconstruction. The collagen matrices are capable of promoting formation of granulation tissue, angiogenesis, and vascularization, and may also be used for the targeted delivery of bioactive agents to a specific tissue or organ.
In addition to its focus on the development and commercialization of post-surgical implants to treat pain and infection, Innocoll is also developing a series of products for wound management using its proprietary, commercialized collagen-based delivery technology, CollaRx. CollaRx products are approved in 45 countries in North America, Europe, South America, Asia and Africa. Innocolls lead product, COLLATAMP® G, is a biodegradable implant that locally delivers high concentration of the broad spectrum antibiotic, gentamicin, for the treatment and prevention of post-surgical acquired infection.
Dr. Michael Myers, president and CEO, commented, The issuing of these patents is indicative of two of Innocolls strategic goals: broadening our intellectual property base and developing improved differentiated products that effectively and safely deliver high local concentrations of active medicines with minimal systemic absorption.
Source: Innocoll, Inc.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.